Digital Health Coach Helps Support an Automated and Improved
Patient Journey for People Living with Parkinson’s Disease
Today, UCB, a global biopharmaceutical company working in
Parkinson’s disease (PD) and other chronic illnesses, and Verint®
Systems Inc. (Nasdaq: VRNT), The Customer Engagement Company™,
announced the release of UCB’s PD Coach app equipped with a
patented conversational, virtual health assistant named “April,”
powered by Verint’s Intelligent Virtual Assistant (IVA)
solution.
April utilizes artificial intelligence (AI) technology to offer
continuous support and encourage patient adherence, transforming
the way patients interact with their healthcare. Verint automation
is powering UCB’s innovative, patient-centric app—a solution that
modernizes patient interactions and improves the overall patient
journey for those with Parkinson’s disease, regardless of
treatment.
Digital health coaches provide an opportunity for modern,
convenient and continuous care, especially for those suffering from
chronic illnesses, such as Parkinson’s disease.
“At UCB, we keep patients at the heart of everything we do. Our
PD Coach, April, offers a vital support system to people living
with and caring for those with Parkinson’s disease, leveraging AI
technology to provide ongoing, personalized support, and access to
the resources they need,” said Mike Davis, Head of UCB’s U.S.
Neurology Patient Value Unit.
Davis continues, “We designed the PD Coach to address specific
challenges that Parkinson’s patients and their caregivers may
face—including its unique ability to learn and adjust to language
and vocabulary for patients with dexterity and speech issues. With
insights from patients on the challenges they face with disease
management, April was created as more than a resource to offer
information. April is designed to build a relationship with the
patient and help deliver what patients value when it comes to their
care.”
PD Coach April leverages Verint’s Alme® Platform and Behavioral
Observation System (BOS) module, allowing her to conduct
evidence-based skillful conversations to actively and safely engage
consumers in a way that feels natural. This platform also provides
the PD Coach with general knowledge related to Parkinson’s disease,
enabling April to speak with patients specifically about the
realities of their chronic disease.
“We are proud to be part of this new, leading-edge digital
innovation that will be accessible to Parkinson’s disease patients
and caregivers. This AI and automation-powered technology creates a
new avenue for patients to turn to for help and guidance that has
the convenience of an app,” says Verint’s Michael Southworth,
general manager, intelligent self-service. “AI and intelligent
assistant technology has the ability to transform healthcare and
access for patients. With April, we’ve built a resource that can
truly meet patients where they are and allow them to take greater
control of their health.”
At launch, April’s key capabilities and features include
journaling and symptom tracking. She also has features relating
directly to Parkinson’s disease and caregiving, with knowledge that
encompasses the following topic areas: PD diagnosis and symptoms,
PD progression, UCB patient services, and patient support groups
and events. As an AI assistant, April will consistently improve and
grow her knowledge with oversight from trainers, personalizing her
care support based on the needs of patients and helping them attain
real health outcomes.
PD Coach is available now in the Apple and Android app stores.
Anyone can download and begin using this digital health coach to
help manage Parkinson’s disease.
To learn more about UCB and April, visit: www.ucb-usa.com. For
more information about Verint’s Intelligent Self-Service automation
portfolio, click here.
About UCB
At UCB, everything we do starts with a simple question: “How
will this make a difference to the lives of people living with
severe diseases?” We have a passionate, long-term commitment to
discovering and developing innovative medicines that transform the
lives of people living with severe diseases. We do that by
connecting with patients and their families around the world living
with the physical and social burdens of severe disease. Those
connections offer new perspectives, drive innovation, and offer the
hope of a new generation of therapies that are helping to transform
lives.
With a team of approximately 7,500 employees and operations in
more than 40 countries, we are a global biopharmaceutical company
investing more than a quarter of our revenue in cutting-edge
scientific research to meet unmet patient needs. Global
headquarters are in Brussels, Belgium, with U.S. headquarters in
Atlanta, Georgia. Additional U.S. UCB sites include global clinical
development at our Research Triangle Park, North Carolina campus
(UCB Biosciences, Inc.), and research supporting UCB’s pipeline in
Cambridge, Massachusetts.
About Verint Systems Inc.
Verint® (Nasdaq: VRNT) is a global leader in Actionable
Intelligence® solutions with a focus on customer engagement
optimization, security intelligence, and fraud, risk and
compliance. Today, over 10,000 organizations in more than 180
countries—including over 85 percent of the Fortune 100—count on
intelligence from Verint solutions to make more informed, effective
and timely decisions. Learn more about how we’re creating A Smarter
World with Actionable
Intelligence® at www.verint.com.
This press release contains “forward-looking statements,”
including statements regarding expectations, predictions, views,
opportunities, plans, strategies, beliefs, and statements of
similar effect relating to Verint Systems Inc. These
forward-looking statements are not guarantees of future performance
and they are based on management’s expectations that involve a
number of risks, uncertainties and assumptions, any of which could
cause actual results to differ materially from those expressed in
or implied by the forward-looking statements. For a detailed
discussion of these risk factors, see our Annual Report on Form
10-K for the fiscal year ended January 31, 2018, our Quarterly
Report on Form 10-Q for the quarter ended July 31, 2018, and other
filings we make with the SEC. The forward-looking statements
contained in this press release are made as of the date of this
press release and, except as required by law, Verint assumes no
obligation to update or revise them or to provide reasons why
actual results may differ.
VERINT, ACTIONABLE INTELLIGENCE, THE CUSTOMER ENGAGEMENT
COMPANY, NEXT IT, OPINIONLAB, TERROGENCE, SENSECY, CUSTOMER
ENGAGEMENT SOLUTIONS, CYBER INTELLIGENCE SOLUTIONS, EDGEVR,
RELIANT, VANTAGE, STAR-GATE, SUNTECH, and VIGIA are trademarks or
registered trademarks of Verint Systems Inc. or its subsidiaries.
Other trademarks mentioned are the property of their respective
owners.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181115005077/en/
UCB Media RelationsErica PuntelErica.Puntel@ucb.com
Verint Media RelationsAmy CurryAmy.curry@verint.com
Verint Systems (NASDAQ:VRNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Verint Systems (NASDAQ:VRNT)
Historical Stock Chart
From Jul 2023 to Jul 2024